Veru (VERU)

• Market cap: $53.9M
• 1 day: -7.07%
• 5 days: -10.94%
• 1 month: -2.56%
• 3 months: -41.03%
• 6 months: -31.05%
• Year to date: -47.55%
• 1 year: -56.32%
• 5 years: -88.13%
• 10 years: -75.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Employees: 210

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.72% less ownership

Funds ownership: 3.24% [Q1] → 2.52% (-0.72%) [Q2]

5% less funds holding

Funds holding: 128 [Q1] → 121 (-7) [Q2]

8% less capital invested

Capital invested by funds: $23.2M [Q1] → $21.5M (-$1.76M) [Q2]

15% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 34

69% less call options, than puts

Call options by funds: $202K | Put options by funds: $662K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20
• Avg. target: $20
• High target: $20

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Gary Nachman

$20

Outperform Maintained

13 Aug 2025